

Preclinical study of CLDN18.2 targeting antibody-drug conjugate for gastric cancer treatment

AbTis Co., Ltd.



ONCOLOGY	Preclinical
Product Type	Antibody Drug Conjugate (ADC)
Indication	CLDN18.2-positive gastric cancer and pancreatic cancer
Target	CLDN18.2
MoA(Mechanism of Action)	Binding to CLDN18.2 antigen → Internalization → Cleaved and released active payload(MMAE) in lysosome → Cancer cell death by MMAE
Competitiveness	<ul style="list-style-type: none"> AbClick® linker: Site-selective conjugation to unmodified Ab with a defined DAR and available to adjust PK property of ADC products Highest TI: Expected to have the highest, more than 26, Therapeutic Index (TI) of CLDN18.2 ADC among the competitors
Development Stage	Preclinical
Route of Administration	IV infusion